Source:http://linkedlifedata.com/resource/pubmed/id/15806191
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1212
|
pubmed:dateCreated |
2005-4-4
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
1175-8716
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
1
|
pubmed:volume |
118
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
U1395
|
pubmed:meshHeading |
pubmed-meshheading:15806191-Cardiovascular Diseases,
pubmed-meshheading:15806191-Cyclooxygenase Inhibitors,
pubmed-meshheading:15806191-Humans,
pubmed-meshheading:15806191-Insurance, Pharmaceutical Services,
pubmed-meshheading:15806191-New Zealand,
pubmed-meshheading:15806191-Risk,
pubmed-meshheading:15806191-Risk Assessment
|
pubmed:year |
2005
|
pubmed:articleTitle |
COX-2 inhibitors--second, do some good.
|
pubmed:publicationType |
Letter,
Comment
|